Get the Stockscreener App
0.272
2.51%
-0.007
IGC Pharma Inc stock is traded at $0.272, with a volume of 455.30K.
It is down -2.51% in the last 24 hours and down -3.20% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.279
Open:
$0.2786
24h Volume:
455.30K
Relative Volume:
0.38
Market Cap:
$28.39M
Revenue:
$1.27M
Net Income/Loss:
$-7.12M
P/E Ratio:
-5.2107
EPS:
-0.0522
Net Cash Flow:
$-5.28M
1W Performance:
-3.17%
1M Performance:
-3.20%
6M Performance:
-9.42%
1Y Performance:
-34.46%
1-Day Range:
$0.2693
$0.2839
1-Week Range:
$0.269
$0.2941
52-Week Range:
$0.242
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.272 | 28.39M | 1.27M | -7.12M | -5.28M | -0.0522 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
IGC Pharma Inc Stock (IGC) Latest News
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow - Black Hills Pioneer
IGC Pharma Showcases AI Portfolio at AAIC 2026 - ACCESS Newswire
IGC Pharma puts AI tools on display for Alzheimer’s research in London - Stock Titan
IGC Pharma (NYSE: IGC) CEO Discusses AI, Alzheimer’s Drug Development and Key 2026 Catalysts on The Street Podcast - Sweetwater Reporter
IGC Pharma (NYSE: IGC) CEO Discusses AI, Alzheimer's Drug - openPR.com
FinancialContentIGC Pharma (NYSE: IGC) CEO Discusses AI, Alzheimer’s Drug Development and Key 2026 Catalysts on The Street Podcast - FinancialContent
IGC Pharma (NYSE: IGC) CEO discusses AI, Alzheimer's drug development and key 2026 catalysts on The Street podcast - MSN
IGC: CEO and CFO Acquire 4.27 Million Shares in Company Stock - GuruFocus
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company - BioSpace
IGC Pharma CEO, finance chief buy $1.15M of common stock - MSN
IGC Pharma chief executives swap $1.15M debt for restricted shares - Stock Titan
IGC Pharma Executives Convert Debt Into Equity Shares - TipRanks
Executives convert $1,154,210 owed into IGC (NYSE: IGC) stock - Stock Titan
IGC Pharma Converts $1.15M Insider Debt Into Equity at $0.27 in Private Issuance - TradingView
IGCIGC Pharma Inc Revenue Breakdown - Finviz
IGC Pharma (NYSE: IGC) CEO and CFO Acquire More Than 4.2 Million Shares - marketscreener.com
Form 4 IGC Pharma Inc For: 1 July By Investing.com - Investing.com Nigeria
IGC Pharma (IGC) CEO converts $601K company debt into 2.23M shares - Stock Titan
Debt-for-equity swap gives IGC Pharma (IGC) PFO 2.0M new shares - Stock Titan
Stocks Under $1: TNMG, SRFM, PRSO, KNDI, IGC Offer Multibagger Potential as AI Boom Accelerates - openPR.com
MultiBagger MicroCaps IGC, RCT, PBK, HUMA, PRSO Stocks to Watch Now - openPR.com
IGC Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock UptickReturn On Capital - dars.gov.et
Enterprise value to revenue forward of IGC Pharma, Inc. – TRADEGATE:IGS1 - TradingView
IGC Pharma, Inc. Actuals & Estimates (AMEX:IGC) - TradingView
IGC Pharma, Inc. Actuals & Estimates (SWB:IGS1) - TradingView
Enterprise value to EBITDA forward of IGC Pharma, Inc. – AMEX:IGC - TradingView
Enterprise value to EBITDA forward of IGC Pharma, Inc. – TRADEGATE:IGS1 - TradingView
IGC Pharma, Inc. Actuals & Estimates (DUS:IGS1) - TradingView
Enterprise value to EBIT forward of IGC Pharma, Inc. – AMEX:IGC - TradingView
IGC Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of IGC Pharma, Inc. – TRADEGATE:IGS1 - TradingView
Enterprise value to EBIT forward of IGC Pharma, Inc. – TRADEGATE:IGS1 - TradingView
IGC Pharma’s (NYSE American: IGC) AI Platform Cuts Alzheimer’s Research by 90%, Accelerating Drug Discovery - Barchart.com
IGC Unveils AI Platform to Enhance Alzheimer's Data Integration - GuruFocus
IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow - ACCESS Newswire
IGC Pharma's AI tool cuts Alzheimer’s data prep from 28 hours to 2.5 - Stock Titan
New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA - Mid Florida Newspapers
IGC Pharma Inc (IGC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IGC Pharma Inc (IGC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IGC Pharma Inc (IGC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IGC Pharma Inc (IGC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IGC Pharma Inc (IGC) Institutional Confidence - TradingKey
IGC Pharma Inc (IGC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IGC Pharma Inc (IGC) Valuation: PE, PB & Fair Value Analysis - TradingKey
IGC Pharma Inc (IGC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IGC Pharma Inc (IGC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis - ACCESS Newswire
IGC Reaches Enrollment Milestone in Alzheimer's Dementia Trial - GuruFocus
IGC Pharma (NYSE American: IGC) Alzheimer's Drug Gains Attention After Ascendiant Capital Raises Price Target - openPR.com
IGC Pharma (IGC) Inches Up 1.78% as It Approaches Key ResistanceSwing Entry Signals - newsline.com
Agitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036) | DelveInsight - 富途牛牛
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):